KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biolife Solutions (BLFS) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Biolife Solutions (BLFS) over the last 14 years, with Q3 2025 value amounting to $41000.0.

  • Biolife Solutions' Gains from Investment Securities changed N/A to $41000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $41000.0, marking a year-over-year increase of 11022.44%. This contributed to the annual value of -$4.1 million for FY2024, which is 8577.29% down from last year.
  • Latest data reveals that Biolife Solutions reported Gains from Investment Securities of $41000.0 as of Q3 2025.
  • Biolife Solutions' 5-year Gains from Investment Securities high stood at $2.3 million for Q3 2022, and its period low was -$3.3 million during Q1 2022.
  • In the last 5 years, Biolife Solutions' Gains from Investment Securities had a median value of -$277500.0 in 2021 and averaged -$287000.0.
  • Over the last 5 years, Biolife Solutions' Gains from Investment Securities had its largest YoY gain of 177571.43% in 2022, and its largest YoY loss of 57922.61% in 2022.
  • Quarter analysis of 5 years shows Biolife Solutions' Gains from Investment Securities stood at $1.8 million in 2021, then tumbled by 178.59% to -$1.4 million in 2022, then surged by 70.48% to -$415000.0 in 2023, then surged by 103.37% to $14000.0 in 2024, then surged by 192.86% to $41000.0 in 2025.
  • Its Gains from Investment Securities stands at $41000.0 for Q3 2025, versus $14000.0 for Q1 2024 and -$415000.0 for Q4 2023.